DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Other: Ofatumumab
Other: Covid-19 vaccine

First Posted Date: 2021-04-19

Last Posted Date: 2023-01-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT04847596

Locations: 🇵🇷
Novartis Investigative Site, Guaynabo, Puerto Rico

Study of Diagnostic Performance of [18F]CTT1057 in BCR

Phase 3

Completed

Conditions: Recurrence
Prostate Cancer
Prostatic Neoplasms

Interventions: Drug: [18F]CTT1057
Drug: [68Ga]Ga-PSMA-11

First Posted Date: 2021-04-09

Last Posted Date: 2025-04-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 190

Registration Number: NCT04838613

Locations: 🇺🇸
Explorer Molecular Imaging center, Sacramento, California, United States
🇨🇭
Novartis Investigative Site, Geneve 14, Switzerland

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Phase 2

Completed

Conditions: Prostatic Neoplasms
Prostate Cancer

Interventions: Drug: [18F]CTT1057

First Posted Date: 2021-04-09

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 195

Registration Number: NCT04838626

Locations: 🇨🇭
Novartis Investigative Site, Geneve 14, Switzerland
🇺🇸
Explorer Molecular Imaging center, Sacramento, California, United States

MAP to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia

Conditions: Thrombocytopenia

First Posted Date: 2021-04-08

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04837703

A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: CMK389
Biological: Placebo

First Posted Date: 2021-04-08

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 71

Registration Number: NCT04836858

Locations: 🇪🇸
Novartis Investigative Site, Cordoba, Andalucia, Spain

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: ensovibep

First Posted Date: 2021-04-01

Last Posted Date: 2023-01-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 407

Registration Number: NCT04828161

Locations: 🇮🇳
Durgabai Deshmukh Hospital & Research Centre, Vidyanagar, Hyderabad, India
🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸
Panax Clinical Research, LLC, Miami Lakes, Florida, United States

and more 45 locations

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

Phase 3

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions: Drug: Iptacopan (LNP023)

First Posted Date: 2021-03-29

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT04820530

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Phase 3

Recruiting

Conditions: C3G

Interventions: Drug: Placebo
Drug: iptacopan

First Posted Date: 2021-03-26

Last Posted Date: 2025-03-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT04817618

Locations: 🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Nicklaus Childrens Hospital, Miami, Florida, United States
🇺🇸
Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States

and more 7 locations

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Capmatinib
Drug: Pemetrexed
Drug: Osimertinib
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2021-03-25

Last Posted Date: 2024-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT04816214

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

Phase 2

Terminated

Conditions: Knee Osteoarthritis

Interventions: Biological: LNA043
Biological: canakinumab
Other: Placebo to canakinumab

First Posted Date: 2021-03-24

Last Posted Date: 2024-08-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT04814368

Locations: 🇺🇸
LV Research, Las Vegas, Nevada, United States
🇺🇸
Clinical Res Of W Florida, Clearwater, Florida, United States
🇺🇸
Horizon Clinical Research, La Mesa, California, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy